Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 23

1.

Impact of Interstitial Ni on the Thermoelectric Properties of the Half-Heusler TiNiSn.

Barczak SA, Buckman J, Smith RI, Baker AR, Don E, Forbes I, Bos JG.

Materials (Basel). 2018 Mar 30;11(4). pii: E536. doi: 10.3390/ma11040536.

2.

PerCEN trial participant perspectives on the implementation and outcomes of person-centered dementia care and environments.

Chenoweth L, Jeon YH, Stein-Parbury J, Forbes I, Fleming R, Cook J, Cheah S, Fletcher S, Tinslay L.

Int Psychogeriatr. 2015 Dec;27(12):2045-57. doi: 10.1017/S1041610215001350. Epub 2015 Aug 26.

PMID:
26307245
3.

Ovarian suppression in a marsupial following single treatment with a gonadotrophin-releasing hormone agonist in microspheres.

Witt RR, Forbes IR, McBain J, Rodger JC.

Reprod Fertil Dev. 2016 Oct;28(12):1964-1973. doi: 10.1071/RD14423.

PMID:
26122537
4.

PerCEN: a cluster randomized controlled trial of person-centered residential care and environment for people with dementia.

Chenoweth L, Forbes I, Fleming R, King MT, Stein-Parbury J, Luscombe G, Kenny P, Jeon YH, Haas M, Brodaty H.

Int Psychogeriatr. 2014 Jul;26(7):1147-60. doi: 10.1017/S1041610214000398. Epub 2014 Mar 26.

PMID:
24666667
5.

Reverse cope elimination of hydroxylamines and alkenes or alkynes: theoretical investigation of tether length and substituent effects.

Krenske EH, Davison EC, Forbes IT, Warner JA, Smith AL, Holmes AB, Houk KN.

J Am Chem Soc. 2012 Feb 1;134(4):2434-41. doi: 10.1021/ja211568k. Epub 2012 Jan 17.

6.

Testing the Birth Unit Design Spatial Evaluation Tool (BUDSET) in Australia: a pilot study.

Foureur MJ, Leap N, Davis DL, Forbes IF, Homer CE.

HERD. 2011 Winter;4(2):36-60.

PMID:
21465434
7.

Developing the Birth Unit Design Spatial Evaluation Tool (BUDSET) in Australia: a qualitative study.

Foureur MJ, Leap N, Davis DL, Forbes IF, Homer CE.

HERD. 2010 Summer;3(4):43-57.

PMID:
21165851
8.

Study protocol of a randomised controlled group trial of client and care outcomes in the residential dementia care setting.

Chenoweth L, King M, Luscombe G, Forbes I, Jeon YH, Parbury JS, Brodaty H, Fleming R, Haas M.

Worldviews Evid Based Nurs. 2011 Sep;8(3):153-65. doi: 10.1111/j.1741-6787.2010.00204.x. Epub 2010 Oct 13.

PMID:
20942820
9.

Novel N-Substituted Benzimidazolones as Potent, Selective, CNS-Penetrant, and Orally Active M1 mAChR Agonists.

Budzik B, Garzya V, Shi D, Walker G, Woolley-Roberts M, Pardoe J, Lucas A, Tehan B, Rivero RA, Langmead CJ, Watson J, Wu Z, Forbes IT, Jin J.

ACS Med Chem Lett. 2010 Jun 8;1(6):244-8. doi: 10.1021/ml100105x. eCollection 2010 Sep 9.

10.

The discovery of a series of N-substituted 3-(4-piperidinyl)-1,3-benzoxazolinones and oxindoles as highly brain penetrant, selective muscarinic M1 agonists.

Johnson DJ, Forbes IT, Watson SP, Garzya V, Stevenson GI, Walker GR, Mudhar HS, Flynn ST, Wyman PA, Smith PW, Murkitt GS, Lucas AJ, Mookherjee CR, Watson JM, Gartlon JE, Bradford AM, Brown F.

Bioorg Med Chem Lett. 2010 Sep 15;20(18):5434-8. doi: 10.1016/j.bmcl.2010.07.097. Epub 2010 Jul 30.

PMID:
20709550
11.

The relationship between birth unit design and safe, satisfying birth: developing a hypothetical model.

Foureur M, Davis D, Fenwick J, Leap N, Iedema R, Forbes I, Homer CS.

Midwifery. 2010 Oct;26(5):520-5. doi: 10.1016/j.midw.2010.05.015. Epub 2010 Aug 7.

PMID:
20692742
12.

2' biaryl amides as novel and subtype selective M1 agonists. Part I: Identification, synthesis, and initial SAR.

Budzik B, Garzya V, Shi D, Foley JJ, Rivero RA, Langmead CJ, Watson J, Wu Z, Forbes IT, Jin J.

Bioorg Med Chem Lett. 2010 Jun 15;20(12):3540-4. doi: 10.1016/j.bmcl.2010.04.128. Epub 2010 May 17.

PMID:
20483611
13.

2' biaryl amides as novel and subtype selective M1 agonists. Part II: Further optimization and profiling.

Budzik B, Garzya V, Shi D, Walker G, Lauchart Y, Lucas AJ, Rivero RA, Langmead CJ, Watson J, Wu Z, Forbes IT, Jin J.

Bioorg Med Chem Lett. 2010 Jun 15;20(12):3545-9. doi: 10.1016/j.bmcl.2010.04.127. Epub 2010 May 17.

PMID:
20483599
14.

Antipsychotic polypharmacy does not increase the risk for side effects.

Ganesan S, Taylor R, Rabheru K, Forbes I, Dumontet J, Procyshyn RM.

Schizophr Res. 2008 Jan;98(1-3):323-4. Epub 2007 Oct 22. No abstract available.

PMID:
17950576
15.

States of uncertainty: governing the empire of biotechnology.

Forbes I.

New Genet Soc. 2006 Apr;25(1):69-88.

PMID:
17312633
16.

Studies towards the identification of a new generation of atypical antipsychotic agents.

Garzya V, Forbes IT, Gribble AD, Hadley MS, Lightfoot AP, Payne AH, Smith AB, Douglas SE, Cooper DG, Stansfield IG, Meeson M, Dodds EE, Jones DN, Wood M, Reavill C, Scorer CA, Worby A, Riley G, Eddershaw P, Ioannou C, Donati D, Hagan JJ, Ratti EA.

Bioorg Med Chem Lett. 2007 Jan 15;17(2):400-5. Epub 2006 Oct 19.

PMID:
17084080
17.

Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties.

Wood MD, Scott C, Clarke K, Westaway J, Davies CH, Reavill C, Hill M, Rourke C, Newson M, Jones DN, Forbes IT, Gribble A.

Eur J Pharmacol. 2006 Sep 28;546(1-3):88-94. Epub 2006 Jul 21.

PMID:
16925992
18.
19.

CCR2: characterization of the antagonist binding site from a combined receptor modeling/mutagenesis approach.

Berkhout TA, Blaney FE, Bridges AM, Cooper DG, Forbes IT, Gribble AD, Groot PH, Hardy A, Ife RJ, Kaur R, Moores KE, Shillito H, Willetts J, Witherington J.

J Med Chem. 2003 Sep 11;46(19):4070-86.

PMID:
12954060
20.

SB-656104-A, a novel selective 5-HT7 receptor antagonist, modulates REM sleep in rats.

Thomas DR, Melotto S, Massagrande M, Gribble AD, Jeffrey P, Stevens AJ, Deeks NJ, Eddershaw PJ, Fenwick SH, Riley G, Stean T, Scott CM, Hill MJ, Middlemiss DN, Hagan JJ, Price GW, Forbes IT.

Br J Pharmacol. 2003 Jun;139(4):705-14.

Supplemental Content

Loading ...
Support Center